Eterna Therapeutics Inc. (NASDAQ:ERNA – Get Free Report) saw a significant growth in short interest in September. As of September 15th, there was short interest totalling 36,600 shares, a growth of 10.2% from the August 31st total of 33,200 shares. Based on an average trading volume of 8,900 shares, the short-interest ratio is currently 4.1 days. Currently, 1.3% of the shares of the company are short sold.
Eterna Therapeutics Stock Performance
Shares of ERNA traded down $0.05 during mid-day trading on Tuesday, hitting $1.00. 17,779 shares of the company’s stock were exchanged, compared to its average volume of 13,618. Eterna Therapeutics has a fifty-two week low of $0.84 and a fifty-two week high of $2.63. The firm has a market capitalization of $5.41 million, a P/E ratio of -0.23 and a beta of 4.43. The business’s 50 day moving average is $1.64 and its two-hundred day moving average is $1.89. The company has a current ratio of 0.37, a quick ratio of 0.37 and a debt-to-equity ratio of 3.03.
Eterna Therapeutics (NASDAQ:ERNA – Get Free Report) last announced its earnings results on Tuesday, August 13th. The company reported ($1.02) earnings per share for the quarter. Eterna Therapeutics had a negative return on equity of 1,466.71% and a negative net margin of 14,765.43%. The business had revenue of $0.05 million for the quarter.
Institutional Investors Weigh In On Eterna Therapeutics
About Eterna Therapeutics
Eterna Therapeutics Inc, a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited.
Read More
- Five stocks we like better than Eterna Therapeutics
- What is Put Option Volume?
- Why Lennar Stock Could Be the Best Play in the Housing Market
- Basic Materials Stocks Investing
- 2 Energy Stocks Fueling the AI Datacenter Boom
- With Risk Tolerance, One Size Does Not Fit All
- Will Marinus Pharmaceuticals Be the Next Big Winner in Biotech?
Receive News & Ratings for Eterna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eterna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.